Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Earnings

BioSyent Schedules Fourth Quarter and Full Year 2025 Earnings Release for March 19, 2026

By The Northwire Desk — AI Analysis Mar 12, 2026 · 17:30 RX · 15.7 BioSyent Inc.
RX · Price

Executive Summary

  • BioSyent Inc. will release its Q4 2025 and full‑year 2025 financial results on Thursday, March 19, 2026 after market hours.
  • A presentation of the results by President & CEO René Goehrum will be posted on the Company’s website concurrent with the release.

Key Details

  • Announcement date: March 12, 2026 (Globe Newswire).
  • Reporting period: Fourth quarter and full year ended December 31, 2025.
  • Release schedule: Results to be disclosed after market close on March 19, 2026.
  • Presentation: CEO René Goehrum will provide a slide deck covering the Q4 and FY 2025 results; it will be available on BioSyent’s website on the same day.
  • Contact for investors: René C. Goehrum, President & CEO – email [email protected], phone 905‑206‑0013.

Notable Quotes

(No quotes were included in the release.)

Read the original news release →

More from BioSyent Inc.

May 19, 2026 · 09:52

BioSyent enters endocrinology with sole-source liquid levothyroxine — a niche launch, but the upside hinges on Tibella/FeraMAX still doing the heavy lifting.

Regulatory May 14, 2026 · 18:00

BioSyent’s Q1 Shows Oral Science Deal Paying Off, but Pharma Core Holds Steady

Earnings Mar 19, 2026 · 17:30

BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025

Earnings Mar 02, 2026 · 21:07

BioSyent closes Oral Science acquisition, grants RSUs

M&A / Property Mar 02, 2026 · 08:30

BioSyent Announces Closing of the Acquisition of Oral Science Inc.

M&A / Property Feb 09, 2026 · 17:54

BioSyent to acquire Oral Science for $25.5-million

M&A / Property